2 Information about lutetium (177Lu) oxodotreotide
|
Marketing authorisation indication |
Lutetium (177Lu) oxodotreotide (Lutathera, AAA, referred to as lutetium) is indicated for 'unresectable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP NETs) in adults'. |
|---|---|
|
Dosage in the marketing authorisation |
Lutetium is administered as an intravenous infusion. A single cycle consists of 4 infusions of 7.4 gigabecquerels (GBq). The recommended interval between infusions is 8 weeks. |
|
Price |
£71,500.00 for 4 administrations of 7.4 GBq (excluding VAT; company submission). The company has a commercial arrangement. This makes lutetium available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount. |